FY2025 EPS Estimates for Aethlon Medical Boosted by Analyst

Aethlon Medical, Inc. (NASDAQ:AEMD) – Equities research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Aethlon Medical in a report released on Wednesday, February 19th. HC Wainwright analyst V. Bernardino now expects that the medical equipment provider will post earnings per share of ($0.73) for the year, up from their previous forecast of ($0.92). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2025 earnings at ($0.13) EPS and FY2026 earnings at ($0.49) EPS.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09.

Separately, StockNews.com upgraded Aethlon Medical to a “sell” rating in a report on Wednesday.

Aethlon Medical Stock Performance

Shares of AEMD opened at $0.60 on Friday. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.85. The stock’s 50-day moving average price is $0.65 and its two-hundred day moving average price is $0.49.

Hedge Funds Weigh In On Aethlon Medical

Several institutional investors have recently modified their holdings of AEMD. Allegiance Financial Group Advisory Services LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at about $26,000. Virtu Financial LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at about $81,000. Renaissance Technologies LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at about $25,000. Sassicaia Capital Advisers LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at about $31,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at about $186,000. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.